DEF 14A: Mirum Pharmaceuticals Sets Date for 2024 Annual Stockholders Meeting

Mirum Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, in a hybrid format.

Summary

• Mirum Pharmaceuticals has announced its 2024 Annual Meeting of Stockholders, scheduled for June 5, 2024, at 9:00 a.m. Pacific Time.
• The meeting will be held in a hybrid format, allowing both in-person attendance at the company's headquarters in Foster City, California, and online participation via live webcast.
• Stockholders of record as of April 10, 2024, are eligible to vote on several key proposals.
• These proposals include the election of three Class II director nominees, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• Additionally, stockholders will provide an advisory vote on the preferred frequency of future advisory votes on executive compensation.
• The board recommends voting in favor of all director nominees, ratifying the auditor selection, approving executive compensation, and holding say-on-pay votes every year.
• Proxy materials are available online at www.proxyvote.com, and stockholders can vote by phone, internet, or mail.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming stockholders meeting and related proposals. The board's recommendations suggest a positive outlook on the company's performance and governance.

Positives

• The company is providing a hybrid meeting format to allow for greater stockholder participation.
• The board is recommending votes in favor of all proposals, indicating confidence in the company's direction and governance.
• The board has determined that eight directors are independent, ensuring strong corporate governance.
• The company has a clawback policy in place, allowing for the recovery of compensation in the event of financial restatements due to misconduct.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties, as detailed in the company's SEC filings.
• The advisory vote on executive compensation is non-binding, meaning the board is not obligated to follow the stockholders' recommendation.
• The company's success depends on attracting, retaining, and motivating key employees, consultants and directors.

Future Outlook

The company expects to conduct its next say-on-pay vote at the 2025 annual meeting if stockholders approve the One Year option.

Management Comments

• Christopher Peetz, Chief Executive Officer, cordially invites stockholders to attend the meeting in person or virtually.
• The Board believes that it is in the best interest of the Company and its stockholders for Mr. Grey continue to serve as Chair of the Board.

Industry Context

Mirum Pharmaceuticals operates in the biopharmaceutical industry, focusing on developing and commercializing therapies for liver diseases. The company's performance is influenced by factors such as regulatory approvals, market competition, and the success of its commercialized products.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, it mentions that the compensation policies and decisions are consistent with current market practices.
• The document mentions several comparable companies in the biographies of the directors, including Adverum Biotechnologies, Allergan, BioMarin Pharmaceutical Inc., Bristol-Myers Squibb, Amgen, Horizon Therapeutics, and others.

Management Changes

Corporate Governance

Related Party Transactions

• Frazier Life Sciences and Deerfield Healthcare Innovations Fund, L.P., both greater than 5% holders, participated in the company's follow-on public offering and convertible notes offering, respectively.
• The company is party to an Investors Rights Agreement with certain holders of its capital stock, including entities affiliated with Frazier.

Stakeholder Impact

• Stockholders have the opportunity to vote on key proposals that will shape the company's governance and direction.
• Executive compensation decisions impact the alignment of management's interests with those of the stockholders.
• The company's performance and strategic decisions affect employees, customers, and other stakeholders.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting of Stockholders on June 5, 2024.
• The company will file a Form 8-K to report the final voting results within four business days after the Annual Meeting.

Key Dates

Keywords

stockholders meeting, proxy statement, board of directors, executive compensation, corporate governance, director election, auditor ratification, Mirum Pharmaceuticals